Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1996-04-01
1999-02-09
Scheiner, Toni R.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 21, A61K 3817
Patent
active
058694455
ABSTRACT:
Compounds and compositions for eliciting or enhancing immune reactivity to HER-2
eu protein are disclosed. The compounds include polypeptides and nucleic acid molecules encoding such peptides. The compounds may be used for the prevention or treatment of malignancies in which the HER-2
eu oncogene is associated.
REFERENCES:
patent: 3766162 (1973-10-01), Spector
patent: 3791932 (1974-02-01), Schuurs et al.
patent: 3817837 (1974-06-01), Rubenstein et al.
patent: 3850752 (1974-11-01), Schuurs et al.
patent: 3901654 (1975-08-01), Gross
patent: 3935074 (1976-01-01), Rubenstein et al.
patent: 3984533 (1976-10-01), Uzgiris
patent: 3996345 (1976-12-01), Ullman et al.
patent: 4034074 (1977-07-01), Miles
patent: 4098876 (1978-07-01), Piasio et al.
patent: 4233402 (1980-11-01), Maggio et al.
patent: 4452901 (1984-06-01), Gordon et al.
patent: 5320947 (1994-06-01), Cheever et al.
patent: 5401638 (1995-03-01), Carney et al.
Fisk et al., "Oligopeptide Induction of a Cytotoxic T Lymphocyte Response to HER-2/Neu Proto-oncogene in Vitro," Cellular Immunology 157:415-427, 1994.
Ioannides et al., "Cytotoxic T-Cell Clones Isolated from Ovarian Tumour Infiltrating Lymphocytes Recognize Common Determinants on Non-Ovarian Tumour Clones," Scand. J. Immunol. 37: 413-424, 1993.
Alper et al., "The Presence of c-erbB-2 Gene Product-related Protein in Culture Medium Conditioned by Breast Cancer Cell Line SK-BR-3," Cell Growth & Differentiation 1:591-599, 1990.
Bargmann et al., "The neu oncogene encodes an epidermal growth factor receptor-related protein," Nature 319:226-230, 1986.
Baselga et al., "Phase II Study of Weekly Intravenous Recombinant Humanized Anti-p185.sup.HER2 Monoclonal Antibody in Patients With HER2
eu-Overexpressing Metastatic Breast Cancer," Journal of Clinical Oncology 14(3): 737-744, 1996.
Ben-Mahrez et al., "Circulating Antibodies Against C-myc Oncogene Product In Sera Of Colorectal Cancer Patients," Int. J. Cancer 46: 35-38, 1990.
Ben-Mahrez et al., "Detection of circulating antibodies against c-myc protein in cancer patient sera," Br. J. Cancer 57: 529-534, 1988.
Bishop and Orosz, "Limiting Dilution Analysis For Alloreactive, TCGF-Secretory T Cells. Two Related LDA Methods That Discriminate Between Unstimulated Precursor T Cells and In Vivo-Alloactivated T Cells," Transplantation 47(4): 671-677, 1989.
Bodmer, W., "T-Cell Immune Responses to Cancer--A New Look," Human Immunology 30:259-261, 1991.
Bowen-Pope et al., "Production of platelet-derived growth factor-like molecules and reduce expression of platelet-derived growth factor receptors accompany transformation by a wide spectrum of agents," Proc. Natl. Acad. Sci. USA 81: 2396-2400, 1984.
Brooks et al., "Human lymphocyte markers defined by antibodies derived from somatic cell hybrids," Clin. exp. Immunol. 39: 477-485, 1980.
Brown et al., "Protein Antigens of Normal and Malignant Human Cells Identified by Immunoprecipitation with Monoclonal Antibodies," Journal of Biological Chemistry 255(11): 4980-4983, 1980.
Burnette et al., "Western Blotting: Electropheretic Transfer of Proteins from Sodium Dodecyl Sulfate-Palyacrylamide Gels to Unmodified Nitrocellulose and Radiographic Detection with Antibody and Radioiodinated Protein A," Analytical Biochemistry 112: 195-203, 1981.
Coussens et al., "Tyrosine Kinase Receptor with Extensive Homology to EGF Receptor Shares Chromosomal Location with neu Oncogene," Science 230: 1132-1139, 1985.
Dhut et al, "BCR-ABL and BCR Proteins: Biochemical Characterization and Localization," Leukemia 4(11): 745-750, 1990.
Disis et al., "Existent T-Cell and Antibody Immunity to HER-2
eu Protein in Patients With Breast Cancer," Cancer Res. 54: 16-20, 1994.
Falk et al., "Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules," Nature 351: 290-296, 1991.
Feller and de la Cruz, "Identifying antigenic T-cell sites," Nature 349: 720-721, 1991.
Flanagan and Leder, "neu protooncogene fused to an immunoglobulin heavy chain gene requires immunoglobulin light chain for cell surface expression and oncogenic transformation," Proc. Natl. Acad. Sci. USA 85: 8057-8061, 1998.
Iglehart et al., "Increased erbB-2 Gene Copies and Expression in Multiple Stages of Breast Cancer," Cancer Research 50: 6701-6707, 1990.
Ioannides et al., "Antigens Recognized by T cells in Ovarian Cancer," in Abstacts of the Fourth International Conference of Anticancer Research, 21-25 Oct. 1992, Rethymnon, Crete, Greece, p. 1870.
Ioannides et al., "CTL Clones Isolated from Ovarian Tumor Infiltrating Lymphocytes can Recognize Peptides with Sequences Corresponding to the HER2
eu Gene Product," FASEB Journal 6: A1404, Abstract No. 2711, 1992.
Ioannides et al., "T-Cell Recognition of Oncogene Products: A New Strategy for Immunotherapy," Molecular Carcinogenesis 6: 77-82, 1992.
Ioannides, C.G., "Antigens and vaccines of female genital cancers (Meeting abstract)," Cancerlit Database Abstract No. ICDB/93690682, 1992.
Ioannides et al., "Cytotoxic T Cells Isolated From Ovarian Malignant Ascites Recognize a Peptide Derived From the HER-2
eu Proto-oncogene," Cell. Immunol. 151: 225-234, 1993.
Kallioniemi et al., "ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization," Proc. Natl. Acad. Sci. 89: 5321-5325, 1992.
Kerns et al., "c-erbB-2 Expression In Breast Cancer Detected by Immunoblotting and Immunohistochemistry," Journal of Histochemistry and Cytochemistry 38(12): 1823-1830, 1990.
Laemmli, U., "Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4," Nature 227: 680-685, 1970.
Leitzel et al., "Elevated Soluble c-erbB2 Antigen Levels in the Serum and Effusions of a Proportion of Breast Cancer Patients," Journal of Clinical Oncology 10(9): 1436-1443, 1992.
Lichtenstein et al., "Effects of .beta.-2 Microglobulin Anti-sense oligonucleotides on Sensitivity of HER2
eu Oncogene-Expressing and Nonexpressing Target Cells to Lymphocyte-Mediated Lysis," Cellular Immunology 141: 219-232, 1992.
Lippman, M., "Potential Contributions of Breast Cancer Biology to Management of Breast Cancer", Advances in Oncology 8(3): 26-28, 1992.
Maguire and Greene, "The neu (c-erbB-2) Oncogene," Seminars in Oncology 16(2): 148-155, 1989.
Margalit et al., "Prediction Of Immunodominant Helper T Cell Antigenic Sites From The Primary Sequence," Journal of Immunology 138(7): 2213-2229, 1987.
McGlynn et al., "Large-scale purification and characterisation of a recombinant epidermal growth-factor receptor protein-tyrosine kinase. Modulation of activity by multiple factors," Eur. J. Biochem. 207: 265-275, 1992.
McKenzie et al., "Induction of Antitumor Immunity by Immunization with a Vaccinia Virus Vector Expressing and Oncogene-encoded Product," in Vaccines 88, Cold Spring Harbor Laboratory, 1988, pp. 19-23.
Mietzner et al., "Purification and Characterization of the Major Iron-Regulated Protein Expressed By Pathogenic Neisseriae," Journal of Experimental Medicine 165: 1041-1057, 1987.
Mori et al., "In vitro and in vivo Release of Soluble erbB-2 Protein from Humnan Carcinoma Cells," Japanese Journal of Cancer Research 81: 489-494, 1990.
Paik et al., "Pathologic Findings From the National Surgical Adjuvant Breast and Bowel Project: Prognostic Significance of erbB-2 Protein Overexpression in Primary Breast Cancer," Journal of Clinical Oncology 8(1): 103-112, 1990.
Parker et al., "Sequence Motifs Important For Peptide Binding To The Human MHC Class I Molecule, HLA-A2," Journal of Immunology 149(11): 3580-3587, 1992.
Press et al., "Expression of the HER-2
eu proto-oncogene in normal human adult and fetal tissues," Oncogene 5: 953-962, 1990.
Raines and Ross, "Platelet-derived Growth Factor. I. High Yields Purification and Evidence for Multiple Forms," Journal of Biological Chemistry 257(9): 5154-5159, 1982.
Riberdy and Cresswell, "The Antigen-Processing Mutant T2 Suggests a Role for MHC-Linked Genes in Class II Antigen Presentation," Journal of Immunology 148(8):2586-2590, 1992.
Rothbard and Taylor, "A sequence pattern common to T cell epitopes," EMBO Journal 7(1) 93-100, 1988.
Semba et al., "A v-erbB-relate
Cheever Martin A.
Disis Mary L.
Johnson Nancy A.
Scheiner Toni R.
University of Washington
LandOfFree
Methods for eliciting or enhancing reactivity to HER-2/neu prote does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for eliciting or enhancing reactivity to HER-2/neu prote, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for eliciting or enhancing reactivity to HER-2/neu prote will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1948445